Literature DB >> 31560543

Simple Structural Modifications Converting a Bona fide MDM2 PROTAC Degrader into a Molecular Glue Molecule: A Cautionary Tale in the Design of PROTAC Degraders.

Jiuling Yang, Yangbing Li, Angelo Aguilar, Zhaomin Liu, Chao-Yie Yang, Shaomeng Wang.   

Abstract

Inducing protein degradation by proteolysis targeting chimeras (PROTACs) has gained tremendous momentum for its promise to discover and develop new therapies. Based upon our previously reported PROTAC MDM2 degraders, we have designed and synthesized additional analogues. Surprisingly, we found that simple structural modifications of MD-222, a bona fide MDM2 PROTAC degrader, converts it into a "molecular glue", as exemplified by MG-277. MG-277 induces only moderate MDM2 degradation and fails to activate wild-type p53 but is highly potent in inhibition of tumor cell growth in a p53-independent manner. Our mechanistic investigation established that MG-277 is not a PROTAC MDM2 degrader but instead works as a molecular glue, inducing degradation of a translation termination factor, GSPT1 to achieve its potent anticancer activity. Our study provides the first example that simple structural modifications can convert a bona fide PROTAC degrader into a molecular glue compound, which has a completely different mechanism of action.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31560543     DOI: 10.1021/acs.jmedchem.9b00846

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  26 in total

Review 1.  PROTACs: great opportunities for academia and industry.

Authors:  Xiuyun Sun; Hongying Gao; Yiqing Yang; Ming He; Yue Wu; Yugang Song; Yan Tong; Yu Rao
Journal:  Signal Transduct Target Ther       Date:  2019-12-24

2.  PROTAC Technology: Opportunities and Challenges.

Authors:  Hongying Gao; Xiuyun Sun; Yu Rao
Journal:  ACS Med Chem Lett       Date:  2020-03-12       Impact factor: 4.345

Review 3.  Proteolysis-targeting chimeras in drug development: A safety perspective.

Authors:  Kevin Moreau; Muireann Coen; Andrew X Zhang; Fiona Pachl; M Paola Castaldi; Goran Dahl; Helen Boyd; Clay Scott; Pete Newham
Journal:  Br J Pharmacol       Date:  2020-02-25       Impact factor: 8.739

4.  Discovery of a Napabucasin PROTAC as an Effective Degrader of the E3 Ligase ZFP91.

Authors:  Maha Hanafi; Xinde Chen; Nouri Neamati
Journal:  J Med Chem       Date:  2021-01-28       Impact factor: 7.446

5.  Mechanistic and Structural Features of PROTAC Ternary Complexes.

Authors:  Ryan Casement; Adam Bond; Conner Craigon; Alessio Ciulli
Journal:  Methods Mol Biol       Date:  2021

6.  PROTACs technology for treatment of Alzheimer's disease: Advances and perspectives.

Authors:  Hiroyuki Inuzuka; Jing Liu; Wenyi Wei; Abdol-Hossein Rezaeian
Journal:  Acta Mater Med       Date:  2022-01-21

7.  Development of Potent and Selective Janus Kinase 2/3 Directing PG-PROTACs.

Authors:  Lisa J Alcock; Yunchao Chang; Jamie A Jarusiewicz; Marisa Actis; Stanley Nithianantham; Anand Mayasundari; Jaeki Min; Dylan Maxwell; Jeremy Hunt; Brandon Smart; Jun J Yang; Gisele Nishiguchi; Marcus Fischer; Charles G Mullighan; Zoran Rankovic
Journal:  ACS Med Chem Lett       Date:  2022-02-21       Impact factor: 4.345

8.  A Cell-Based Target Engagement Assay for the Identification of Cereblon E3 Ubiquitin Ligase Ligands and Their Application in HDAC6 Degraders.

Authors:  Ka Yang; Yu Zhao; Xueqing Nie; Hao Wu; Bo Wang; Chelsi M Almodovar-Rivera; Haibo Xie; Weiping Tang
Journal:  Cell Chem Biol       Date:  2020-05-14       Impact factor: 8.116

Review 9.  Ubiquitin-proteasome system-targeted therapy for uveal melanoma: what is the evidence?

Authors:  Chen-Xi Zhao; Chen-Ming Zeng; Ke Wang; Qiao-Jun He; Bo Yang; Fan-Fan Zhou; Hong Zhu
Journal:  Acta Pharmacol Sin       Date:  2020-06-29       Impact factor: 6.150

10.  A nano-predator of pathological MDMX construct by clearable supramolecular gold(I)-thiol-peptide complexes achieves safe and potent anti-tumor activity.

Authors:  Siqi Yan; Jin Yan; Dan Liu; Xiang Li; Qianyan Kang; Weiming You; Jinghua Zhang; Lei Wang; Zhiqi Tian; Wuyuan Lu; Wenjia Liu; Wangxiao He
Journal:  Theranostics       Date:  2021-05-03       Impact factor: 11.556

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.